Antisense Evidence of Clinical Activity

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.

Miner PB Jr, Wedel MK, Xia S, Baker BF.

Aliment Pharmacol Ther. 2006 May 15;23(10):1403-13.

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.

Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK.

Aliment Pharmacol Ther. 2006 May 15;23(10):1427-34.

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.

van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr.

Aliment Pharmacol Ther. 2006 May 15;23(10):1415-25.

Phase I trial of ISIS 104838, a 2'-Methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-a

Sewell, K.L., Geary, R.S., Baker, B.F., Glover, J.M., Mant, T.G., Yu, R.Z., Tami, J.A., and Dorr, A.

J Pharmacol Exp Ther. 2002 Dec;303(3):1334-43.

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, Alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease.

Yacyshyn, B.R., Chey, W.Y., Goff, J., Salzberg, B. Baerg, R., Buchman, A.L., Tami, J., Yu, R., Gibiansky, E., and Shanahan, W.R.

Gut. 51: 30-36, 2002.

A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS.

Vitravene Study Group.

American Journal of Ophthalmology 133(4): 467-474, 2002.

Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS.

Vitravene Study Group

American Journal of Ophthalmology 133(4): 475-483, 2002.

Safety of intravitreous fomivirsen of treatment of cytomegalovirus retinitis in patients with AIDS.

Vitravene Study Group

American Journal of Ophthalmology 133(4): 484-498, 2002.

Drugs Today (Barc). 2001 Apr;37(4):245-255.

Grillone, L.R. and Lanz, R. Fomivirsen.

Drugs Today (Barc). 2001 Apr;37(4):245-255.

ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1 (ICAM-1).

Shanahan, W.

In: Antisense Drug Technology: Principles, Strategies, and Applications (ed. Crooke, S.T.), pp. 773-794. Marcel Dekker, Inc., New York, 2001.

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

Yacyshyn, B.R., Bowen-Yacyshyn, M.B., Jewell, L., Tami, J.A., Bennett, C.F., Kisner, D.L., and Shanahan, Jr., W.R.

Gastroenterology. 1998 Jun;114(6):1133-42.